Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Hiroki Izumi"'
Autor:
Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-10 (2024)
Abstract The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC patient harboring CLIP1-LTK fusio
Externí odkaz:
https://doaj.org/article/d5116c53bf5a493298d2e20157408e3f
Autor:
Yosuke Kagawa, MD, Takuma Hayashida, MS, Jie Liu, BS, Shunta Mori, MD, Hiroki Izumi, MD, PhD, Shogo Kumagai, MD, PhD, Hibiki Udagawa, MD, PhD, Noboru Hattori, MD, PhD, Koichi Goto, MD, PhD, Susumu S. Kobayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100462- (2023)
Introduction: EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions,
Externí odkaz:
https://doaj.org/article/e3d98b0bb20a49d68b4a9a9c19b6c29e
Autor:
Moriyasu Anai, Chieko Yoshida, Hiroki Izumi, Kei Muramoto, Koichi Saruwatari, Yusuke Tomita, Hidenori Ichiyasu, Takuro Sakagami
Publikováno v:
Respirology Case Reports, Vol 11, Iss 1, Pp n/a-n/a (2023)
Abstract A 29‐year‐old man presented to our hospital with severe eosinophilic asthma. He needed a short OCS burst for exacerbation of asthma once every 1 or 2 months, although he used a high dose of inhaled corticosteroids and a long‐acting bet
Externí odkaz:
https://doaj.org/article/8960c2f29f884a9a9c2ee3f584b99d57
Autor:
Toshinori Ando, Nadia Arang, Zhiyong Wang, Daniela Elena Costea, Xiaodong Feng, Yusuke Goto, Hiroki Izumi, Mara Gilardi, Kazuyo Ando, J. Silvio Gutkind
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-15 (2021)
Ando et al show in head and neck squamous cell carcinoma cells that EGFR activation leads to the phosphorylation of the Hippo pathway component, MOB1 to inhibit LATS1/2 function resulting in YAP/TAZ activation. Further, EGFR-targeting therapies suppr
Externí odkaz:
https://doaj.org/article/33b5d7dcaf814e90908b2ebbb399a0ea
Autor:
Yoki Nakamura, Hiroki Izumi, Takumi Shimizu, Kazue Hisaoka-Nakashima, Norimitsu Morioka, Yoshihiro Nakata
Publikováno v:
Journal of Pharmacological Sciences, Vol 121, Iss 4, Pp 257-271 (2013)
Abstract.: To clarify a role of substance P (SP) in an endogenous pain control mechanism involving the rat striatum, striatal SP release was measured over time by microdialysis following intraplantar injection of 0.4% formalin. A slow-onset but signi
Externí odkaz:
https://doaj.org/article/e200acb09e024b889f0b3e62b79ed15d
Autor:
Luis Paz-Ares, Stephane Champiat, W. Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L. Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemi Reguart, Tatsuya Yoshida, Kai He, Shirish M. Gadgeel, Enriqueta Felip, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek K. Owonikoko
Publikováno v:
Journal of Clinical Oncology. 41:2893-2903
PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03ea734bd56a31a508492cc9cf771688
https://doi.org/10.1200/jco.22.02823
https://doi.org/10.1200/jco.22.02823
Autor:
Yutaro, Tamiya, Tokiko, Nakai, Ayako, Suzuki, Sachiyo, Mimaki, Katsuya, Tsuchihara, Kei, Sato, Kiyotaka, Yoh, Shingo, Matsumoto, Yoshitaka, Zenke, Kaname, Nosaki, Hiroki, Izumi, Yuji, Shibata, Tetsuya, Sakai, Tetsuro, Taki, Saori, Miyazaki, Reiko, Watanabe, Naoya, Sakamoto, Shingo, Sakashita, Motohiro, Kojima, Naozumi, Hashimoto, Masahiro, Tsuboi, Koichi, Goto, Genichiro, Ishii
Publikováno v:
Lung Cancer. 174:125-132
Tertiary lymphoid structures (TLS) are observed in several cancers and are associated with favorable prognosis. This study aimed to examine the clinicopathological, genetic, and gene expression profiles of lung adenocarcinoma patients with TLS.A tota
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1687e21ca3745bd5ac82c06cb6b3a994
https://doi.org/10.1016/j.lungcan.2022.11.001
https://doi.org/10.1016/j.lungcan.2022.11.001
Autor:
Akira Sugimoto, Shingo Matsumoto, Hibiki Udagawa, Ryo Itotani, Yuko Usui, Shigeki Umemura, Kazumi Nishino, Ichiro Nakachi, Shoichi Kuyama, Haruko Daga, Satoshi Hara, Shingo Miyamoto, Terufumi Kato, Jun Sakakibara-Konishi, Eriko Tabata, Taku Nakagawa, Tomoya Kawaguchi, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Koichi Goto
Publikováno v:
Clinical Cancer Research. 29:1506-1514
Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). Experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6cc897d5d43308fd6f8fe4d851c8d24
https://doi.org/10.1158/1078-0432.ccr-22-1749
https://doi.org/10.1158/1078-0432.ccr-22-1749
Autor:
Koichi Goto, Kiyotaka Yoh, Yoshitaka Zenke, Kaname Nosaki, Hiroki Izumi, Yuji Shibata, Tetsuya Sakai, Tomoya Kawaguchi, Taku Nakagawa, Eriko Tabata, Jun Sakakibara-Konishi, Terufumi Kato, Shingo Miyamoto, Satoshi Hara, Haruko Daga, Shoichi Kuyama, Ichiro Nakachi, Kazumi Nishino, Shigeki Umemura, Yuko Usui, Ryo Itotani, Hibiki Udagawa, Shingo Matsumoto, Akira Sugimoto
Purpose:We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid).Experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33abd86977c89fe640712ac7d1e0e1d8
https://doi.org/10.1158/1078-0432.c.6532737.v2
https://doi.org/10.1158/1078-0432.c.6532737.v2
Autor:
Koichi Goto, Kiyotaka Yoh, Yoshitaka Zenke, Kaname Nosaki, Hiroki Izumi, Yuji Shibata, Tetsuya Sakai, Tomoya Kawaguchi, Taku Nakagawa, Eriko Tabata, Jun Sakakibara-Konishi, Terufumi Kato, Shingo Miyamoto, Satoshi Hara, Haruko Daga, Shoichi Kuyama, Ichiro Nakachi, Kazumi Nishino, Shigeki Umemura, Yuko Usui, Ryo Itotani, Hibiki Udagawa, Shingo Matsumoto, Akira Sugimoto
Supplementary Figure S1. Consort diagram. Supplementary Figure S2. Frequency of the targetable gene alterations detected by plasma cfDNA sequencing (A) and tissue assay (B) in squamous cell carcinoma Supplementary Figure S3. Positive percent agreemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c78bd5be2712e7aaaa95c30f42ca0bd
https://doi.org/10.1158/1078-0432.22633112
https://doi.org/10.1158/1078-0432.22633112